Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 10/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150866 | 0.98 | HPGD (0.50) | HPGDHTTLMNAMAPK1GAA | |
| SCHEMBL4164258 | 0.83 | HPGD (0.57) | HPGDHTTGAAALDH1A1MEN1 | |
| SCHEMBL12057625 | 0.79 | GAA (0.53) | HPGDHTTLMNAMAPK1GAA | |
| SCHEMBL4962007 | 0.77 | GAA (0.35) | HPGDHTTMAPK1GAAALDH1A1 | |
| SCHEMBL4164480 | 0.72 | HPGD (0.53) | HPGDHTTLMNAMAPK1GAA | |
| SCHEMBL8124664 | 0.72 | ALDH1A1 (0.60) | HPGDHTTLMNAGAAALDH1A1 | |
| SCHEMBL10330512 | 0.71 | HTT (0.86) | HPGDHTTALDH1A1KMT2ANPSR1 | |
| SCHEMBL2538595 | 0.71 | HTT (0.86) | HPGDHTTALDH1A1KMT2ANPSR1 | |
| SCHEMBL25412667 | 0.71 | NAMPT (0.45) | HPGDLMNAMAPK1GAAALDH1A1 | |
| SCHEMBL30530619 | 0.69 | HTT (0.89) | HPGDHTTALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885LMNA 4492/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | HPGD 272/4885HTT 4858/4885LMNA 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.